These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
96 related articles for article (PubMed ID: 23072299)
1. Flavaglines as potent anticancer and cytoprotective agents. Ribeiro N; Thuaud F; Bernard Y; Gaiddon C; Cresteil T; Hild A; Hirsch EC; Michel PP; Nebigil CG; Désaubry L J Med Chem; 2012 Nov; 55(22):10064-73. PubMed ID: 23072299 [TBL] [Abstract][Full Text] [Related]
2. Flavaglines alleviate doxorubicin cardiotoxicity: implication of Hsp27. Bernard Y; Ribeiro N; Thuaud F; Türkeri G; Dirr R; Boulberdaa M; Nebigil CG; Désaubry L PLoS One; 2011; 6(10):e25302. PubMed ID: 22065986 [TBL] [Abstract][Full Text] [Related]
3. Recent advances in the biology and chemistry of the flavaglines. Ribeiro N; Thuaud F; Nebigil C; Désaubry L Bioorg Med Chem; 2012 Mar; 20(6):1857-64. PubMed ID: 22071525 [TBL] [Abstract][Full Text] [Related]
4. FL3, a Synthetic Flavagline and Ligand of Prohibitins, Protects Cardiomyocytes via STAT3 from Doxorubicin Toxicity. Qureshi R; Yildirim O; Gasser A; Basmadjian C; Zhao Q; Wilmet JP; Désaubry L; Nebigil CG PLoS One; 2015; 10(11):e0141826. PubMed ID: 26536361 [TBL] [Abstract][Full Text] [Related]
5. Use of resveratrol to improve the effectiveness of cisplatin and doxorubicin: study in human gynecologic cancer cell lines and in rodent heart. Rezk YA; Balulad SS; Keller RS; Bennett JA Am J Obstet Gynecol; 2006 May; 194(5):e23-6. PubMed ID: 16647892 [TBL] [Abstract][Full Text] [Related]
7. TVP1022 and propargylamine protect neonatal rat ventricular myocytes against doxorubicin-induced and serum starvation-induced cardiotoxicity. Kleiner Y; Bar-Am O; Amit T; Berdichevski A; Liani E; Maor G; Reiter I; Youdim MB; Binah O J Cardiovasc Pharmacol; 2008 Sep; 52(3):268-77. PubMed ID: 18806608 [TBL] [Abstract][Full Text] [Related]
8. Synthetic analogue of rocaglaol displays a potent and selective cytotoxicity in cancer cells: involvement of apoptosis inducing factor and caspase-12. Thuaud F; Bernard Y; Türkeri G; Dirr R; Aubert G; Cresteil T; Baguet A; Tomasetto C; Svitkin Y; Sonenberg N; Nebigil CG; Désaubry L J Med Chem; 2009 Aug; 52(16):5176-87. PubMed ID: 19655762 [TBL] [Abstract][Full Text] [Related]
9. Procyanidins produce significant attenuation of doxorubicin-induced cardiotoxicity via suppression of oxidative stress. Li W; Xu B; Xu J; Wu XL Basic Clin Pharmacol Toxicol; 2009 Mar; 104(3):192-7. PubMed ID: 19143757 [TBL] [Abstract][Full Text] [Related]
10. Screening of antioxidants from medicinal plants for cardioprotective effect against doxorubicin toxicity. Wattanapitayakul SK; Chularojmontri L; Herunsalee A; Charuchongkolwongse S; Niumsakul S; Bauer JA Basic Clin Pharmacol Toxicol; 2005 Jan; 96(1):80-7. PubMed ID: 15667600 [TBL] [Abstract][Full Text] [Related]
11. The iron chelator Dp44mT does not protect myocytes against doxorubicin. Hasinoff BB; Patel D J Inorg Biochem; 2009 Jul; 103(7):1093-101. PubMed ID: 19535146 [TBL] [Abstract][Full Text] [Related]
12. Discovery of 3,3'-pyrrolidinyl-spirooxindoles as cardioprotectant prohibitin ligands. Elderwish S; Audebrand A; Nebigil CG; Désaubry L Eur J Med Chem; 2020 Jan; 186():111859. PubMed ID: 31735574 [TBL] [Abstract][Full Text] [Related]
13. Flavaglines: potent anticancer drugs that target prohibitins and the helicase eIF4A. Basmadjian C; Thuaud F; Ribeiro N; Désaubry L Future Med Chem; 2013 Dec; 5(18):2185-97. PubMed ID: 24261894 [TBL] [Abstract][Full Text] [Related]
14. Antitumor and antimicrobial activities of some hetero aromatic benzofurans derived from naturally occurring visnagin. El-Nakkady SS; Roaiah HF; El-Serwy WS; Soliman AM; El-Moez SI; Abdel-Rahman AA Acta Pol Pharm; 2012; 69(4):645-55. PubMed ID: 22876607 [TBL] [Abstract][Full Text] [Related]
15. A synthetic derivative of the natural product rocaglaol is a potent inhibitor of cytokine-mediated signaling and shows neuroprotective activity in vitro and in animal models of Parkinson's disease and traumatic brain injury. Fahrig T; Gerlach I; Horváth E Mol Pharmacol; 2005 May; 67(5):1544-55. PubMed ID: 15716464 [TBL] [Abstract][Full Text] [Related]
16. The protective effect of cardiac gene transfer of CuZn-sod in comparison with the cardioprotector monohydroxyethylrutoside against doxorubicin-induced cardiotoxicity in cultured cells. Abou El Hassan MA; Heijn M; Rabelink MJ; van der Vijgh WJ; Bast A; Hoeben RC Cancer Gene Ther; 2003 Apr; 10(4):270-7. PubMed ID: 12679799 [TBL] [Abstract][Full Text] [Related]
17. Urotensin II prevents cardiomyocyte apoptosis induced by doxorubicin via Akt and ERK. Chen YL; Loh SH; Chen JJ; Tsai CS Eur J Pharmacol; 2012 Apr; 680(1-3):88-94. PubMed ID: 22329895 [TBL] [Abstract][Full Text] [Related]
18. Molecular mechanisms and anti-cancer aspects of the medicinal phytochemicals rocaglamides (=flavaglines). Li-Weber M Int J Cancer; 2015 Oct; 137(8):1791-9. PubMed ID: 24895251 [TBL] [Abstract][Full Text] [Related]
19. Enhanced toxicity and ROS generation by doxorubicin in primary cultures of cardiomyocytes from neonatal metallothionein-I/II null mice. Fu Z; Guo J; Jing L; Li R; Zhang T; Peng S Toxicol In Vitro; 2010 Sep; 24(6):1584-91. PubMed ID: 20600803 [TBL] [Abstract][Full Text] [Related]
20. Cytoprotective effect of anthocyanins against doxorubicin-induced toxicity in H9c2 cardiomyocytes in relation to their antioxidant activities. Choi EH; Chang HJ; Cho JY; Chun HS Food Chem Toxicol; 2007 Oct; 45(10):1873-81. PubMed ID: 17524543 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]